NCT01471106View on ClinicalTrials.gov

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

January 21, 2014

Primary Completion Date

January 31, 2024

Study Completion Date

May 30, 2024

Conditions

Breast Cancer

Interventions

DRUG

Dasatinib

"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."

Trial Locations (2)

27708

Duke University, Durham

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Susan G. Komen Breast Cancer Foundation

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER